Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Amgen Inc. (NASDAQ: AMGN).

Full DD Report for AMGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: AMGN)

Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr...
Source: SeekingAlpha
Date: December, 08 2018 09:31
Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend
THOUSAND OAKS, Calif. , Dec. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1 .45 per share dividend for the first quarter of 2019. The dividend will be paid on March 8, 2019 , to all stockholders of record as of the close o...
Source: PR Newswire
Date: December, 07 2018 16:00
EV Charging Gets $240M Push As Trump Threatens Cuts
Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. EV charging: Chevron (CVX) Technology Ventures and American Electric Power (AEP) were among the investors in a ...
Source: SeekingAlpha
Date: December, 01 2018 11:46
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY(TM) (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
THOUSAND OAKS, Calif. and BRUSSELS , Nov. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics...
Source: PR Newswire
Date: November, 30 2018 16:00
Dividend Increases: October 29-November 2, 2018
One way to identify dividend growth stocks for further analysis is to monitor dividend increases. Companies that regularly increase their dividends show confidence in future earnings growth potential. The CCC List provides a good starting point, but I limit the number of stocks to monitor ...
Source: SeekingAlpha
Date: November, 06 2018 13:11
Why We Pass On Amgen
Amgen's stock is the leading iShares Nasdaq Biotechnology ETF ( IBB ) component. However, we don't think that its stock is going to grow faster than other stocks represented in IBB. While other major biotech companies have suffered stock declines due to weakened sales forecast, Amgen has not...
Source: SeekingAlpha
Date: November, 06 2018 11:53
A Migrating Biotech Bear
Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda...
Source: SeekingAlpha
Date: November, 06 2018 08:39
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
THOUSAND OAKS, Calif. , Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER -1 study, evaluating the long-term safety and efficacy of Repatha ® (evolocumab) in patients w...
Source: PR Newswire
Date: November, 05 2018 16:00
Advaxis, Revisited
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Most of my readers will know A...
Source: SeekingAlpha
Date: November, 05 2018 14:01
Provention Bio up 12% on co-development deal with Amgen
Thinly traded micro cap Provention Bio ( PRVB +12.4% ) is up on modestly higher volume in early trade in response to its agreement to co-develop AMG 714 with Amgen ( AMGN +0.9% ) for the treatment of patients with celiac disease that is unresponsive to a gluten-free diet. Provention ha...
Source: SeekingAlpha
Date: November, 05 2018 09:57

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-08195.43196.30197.55194.75352,604,067
2018-05-17173.31174.65175.43172.532,268,360
2017-06-20165.43166.29168.70164.793,857,863
2017-06-19163.10165.09165.22162.693,043,884
2017-06-16163.84162.42164.10161.135,887,244

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-10225,860508,66044.4029Short
2018-12-07263,951535,04249.3328Short
2018-12-06285,097531,67853.6221Short
2018-12-04254,600603,17342.2101Short
2018-12-03339,961940,20336.1583Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AMGN.


About Amgen Inc. (NASDAQ: AMGN)

Logo for Amgen Inc. (NASDAQ: AMGN)

Not available

 

Contact Information

 

 

Current Management

  • Richard Nanula / CFO
  • Steven M. Odre / Secretary

Current Share Structure

  • Market Cap: $116,433,788,992 - 05/14/2018
  • Issue and Outstanding: 661,706,007 - 04/18/2018

 


Recent Filings from (NASDAQ: AMGN)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 17 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 25 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: April, 12 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 11 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 11 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 27 2018

 

 


Daily Technical Chart for (NASDAQ: AMGN)

Daily Technical Chart for (NASDAQ: AMGN)


Stay tuned for daily updates and more on (NASDAQ: AMGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AMGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AMGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AMGN and does not buy, sell, or trade any shares of AMGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/